DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Ramin Rafie, MD is an Internist trained in Geriatric, Hospice & Palliative Medicine.Dr. Rafie was born in Iran and grew up in Los Angeles,...
Chronic pain affects the mental health of young people and it requires continuous and complex self-management that often fails. Happyr Health supports teens with...
John P. Pigott, MD, FACS, currently serves as Chief Innovations Officer/Strategic Business Development for ProMedica and ProMedica Innovations, where he works with thought leaders...
